Detailed dose evidence documented for Desirudin in its monograph — reference only, not dosing recommendations.
Reference only — not a dosing recommendation.
Approved regimen
Approved labeled regimen
Product-, indication-, and jurisdiction-specific — see the monograph
Elective hip replacement: 15 mg SC every 12 h. First dose given 5-15 min prior to surgery (but after induction of regional block anesthesia). Continue for 9-12 days. In moderate renal impairment (CrCl 31–60 mL/min): reduce dose by factor of 3 (5 mg SC q12h). In severe renal impairment (CrCl <31 mL/min): reduce dose by factor of 9 (1.7 mg SC q12h). Monitor aPTT and serum creatinine daily in patients with renal impairment.
Studied in trials
Studied regimens (not recommendations)
Studied in trials — not a recommended dose
Various dose-ranging studies used 10-20 mg SC BID; the 15 mg BID dose was selected as the optimal balance of efficacy and safety.
Not established
What is not established
DVT prophylaxis for knee replacement (not established; phase 3 data limited to hip replacement).
Treatment of established VTE (not labeled).
Use in ACS or PCI (not labeled; bivalirudin used instead for these indications).